Related Experiment Video
Updated: Jan 9, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Current status and clinical usefulness of genomic panel testing using PleSSision-160 in resectable esophageal
Kazuaki Matsui1, Hirofumi Kawakubo1, Satoru Matsuda1
1Department of Surgery, Keio University School of Medicine, 35-banchi, Shinano-machi, Shinjuku-ku, Tokyo, Japan.
Introduction:
The clinical importance of treatment approaches based on genomic sequencing has increased in esophageal cancer. This study aimed to clarify the current status and clinical usefulness of genomic panel testing using PleSSision-160 for resectable esophageal squamous cell carcinoma (ESCC).
Materials And Methods:
Sixty-six tumor tissue samples from 61 patients with ESCC, including prospectively collected 46 surgical samples and retrospectively collected 20 biopsy samples before neoadjuvant chemotherapy, were tested using the PleSSision-160 panel. The associations of mutation profiles with long-term survival and chemotherapy resistance were investigated.
Results:
The top five mutations identified in surgical samples using PleSSision-160 were TP53 (80.4 %), KMT2D (13.0 %), NOTCH1 (13.0 %), EP300 (8.7 %), and AMER1 (8.7 %). Although individual mutations did not show significant associations with long-term survival, patients with high copy number alteration (CNA) status (≥30 counts) had poorer 5-year overall survival (OS) and recurrence-free survival (RFS) compared to those with low CNA status (p = 0.019 and 0.077 for OS and RFS, respectively). Multivariate analyses identified minimally invasive surgery, pStage ≥ III, and high CNA status as independent factors associated with both 5-year OS and RFS.
Conclusion:
This study is the first to investigate postoperative survival and chemotherapy resistance based on genomic panel testing using PleSSision-160 for resectable ESCC. The findings suggested that high CNA status was a risk factor for long-term survival. Compared to previous genomic sequencing studies in ESCC, further investigation using PleSSision-160 appears to be a promising approach.
